ReviewJournal, genetic engineering & biotechnology2025
Exploring the therapeutic potential of microRNAs: targeted gene regulation strategies for enhanced cancer therapy.
Review in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic and Predictive Value of Circulating and Exosomal microRNAs in Ferroptosis-Associated Neurological Conditions: A Systematic Review and Meta-analysis.Molecular neurobiology · 2026Pooled it
- MicroRNA regulation of macrophage polarization in lung cancer: Regulatory networks and therapeutic potential (Review).International journal of oncology · 2026Review
- Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Review
- Extracellular Vesicle-Associated miRNAs in Glioblastoma: Mechanisms, Biomarkers, Therapies, and Links to Neurodegeneration.Cancers · 2026Review
- Pediatric Hepatoblastoma: From Developmental Molecular Mechanisms to Innovative Therapeutic Strategies.Cancers · 2026Review
- MicroRNAs as Mediators of Mechanotransduction: from Fundamental Mechanisms to Therapeutic Applications.Cell biochemistry and biophysics · 2026Review
- MicroRNA‑microbiome cross‑kingdom networks drive inflammatory bowel disease through dynamic regulatory ecosystems (Review).International journal of molecular medicine · 2026Review
- Integrative Bioinformatics Analysis of hsa-miR-21 in Breast Cancer Reveals a Prognostic Hub-Gene Signature.International journal of molecular sciences · 2026Article
- MicroRNAs in Esophageal Cancer: Implications for Diagnosis, Progression, Prognosis and Chemoresistance.International journal of molecular sciences · 2026Review
- Rewriting Tumor Entry Rules: Microfluidic Polyplexes and Tumor-Penetrating Strategies-A Literature Review.Pharmaceutics · 2026Review
- Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.Frontiers in cell and developmental biology · 2026Review
- Crosstalk between innate immune signaling pathways and integrated TLR, NLRP3 inflammasome, cGAS-STING, and NF-κB networks in sepsis.Frontiers in cell and developmental biology · 2026Review
- MicroRNAs in systemic lupus erythematosus: Molecular networks, pathway dysregulation, and therapeutic targeting strategies.Biotechnology notes (Amsterdam, Netherlands) · 2026Review
- MicroRNAs profiling in malaria and arbovirus coinfection: A systematic review protocol.PloS one · 2026Article
- Non-coding RNAs as regulators of chromosomal instability in breast cancer.Frontiers in oncology · 2026Review
- The dual facets of MiRNA in modulating NF-κB in breast cancer.Cancer cell international · 2025Review
- tRNA-derived fragments (tRFs) as key non-coding players in the tumor transcriptome of colorectal cancer: introducing a new suspect responsible for the remaining unknowns of tumor pathology.Medical oncology (Northwood, London, England) · 2025Review
- Unveiling the role of microRNAs, the PI3K/AKT pathway, and their associations in various types of leukemia: a comprehensive review.Blood research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the most significant causes of death worldwide, with conventional therapies often hindered by drug resistance, off-target effects, and systemic toxicity. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as critical regulators of gene expression, influencing various cellular processes such as proliferation, apoptosis, and metastasis. Their dual role as tumor suppressors and oncogenes makes them promising therapeutic targets for cancer treatment. This review explores the therapeutic potential of miRNAs in modulating key cancer pathways and overcoming drug resistance. It delves into strategies like miRNA mimics and antagomiRs to restore normal gene expression, alongside advanced delivery systems, including nanoparticles and exosomes, to ensure targeted, stable, and effective delivery. Furthermore, the challenges associated with miRNA therapy, such as degradation, off-target effects, and immune responses, are discussed. The integration of miRNA-based approaches with existing therapies holds promise for enhancing treatment efficacy and paving the way for personalized cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.